Estonsko - estonština - Ravimiamet

alfasan nederland b.v. - amoksitsilliin+klavulaanhape - tablett - 50mg+12,5mg 100tk; 50mg+12,5mg 50tk; 50mg+12,5mg 10tk; 50mg+12,5mg 250tk; 50mg+12,5mg 30tk

Estonsko - estonština - Ravimiamet

alfasan nederland b.v. - amoksitsilliin+klavulaanhape - tablett - 500mg+125mg 250tk; 500mg+125mg 30tk; 500mg+125mg 10tk; 500mg+125mg 50tk

Estonsko - estonština - Ravimiamet

alfasan nederland b.v. - amoksitsilliin+klavulaanhape - tablett - 250mg+62,5mg 50tk; 250mg+62,5mg 250tk; 250mg+62,5mg 10tk; 250mg+62,5mg 30tk

Evropská unie - estonština - EMA (European Medicines Agency)

merck sharp dohme limited - lamivudine, raltegravir kaaliumi - hiv-nakkused - antivirals for systemic use, antivirals for treatment of hiv infections, combinations - dutrebise on näidustatud kombinatsioonis teiste anti‑retroviral ravimitega inimese immuunpuudulikkuse viiruse (hiv‑1) infektsiooniga täiskasvanutel, noorukitel ja lastel alates 6 aastat ja kehakaaluga vähemalt 30 kg ilma praegu või varem anamneesis viirusevastaste ravimite insti (integraasi ülekande inhibiitorite) ja nrti (nukleosiidi pöördtranskriptaasi inhibiitorite) suhtes (vt lõigud 4 klassid. 2, 4. 4 ja 5.

Evropská unie - estonština - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Estonsko - estonština - Ravimiamet

novartis baltics sia - tobramütsiin - silmatilgad, lahus - 3mg 1ml 5ml 1tk

Estonsko - estonština - Ravimiamet

novartis baltics sia - tobramütsiin - silmasalv - 3mg 1g 3.5g 1tk

Estonsko - estonština - Ravimiamet

globalex pharma oÜ - tobramütsiin - silmasalv - 3mg 1g 3.5g 1tk

Evropská unie - estonština - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

Estonsko - estonština - Ravimiamet

aspen pharma trading limited - merkaptopuriin - tablett - 50mg 25tk